OpenQ, a provider of solutions to enable life sciences and health companies to overcome compliance and exposure risks, introduced OpenQ SafeGuard™, a social enterprise compliance suite for managing social compliance risk. This patent-pending technology allows companies with social compliance risk to consolidate internal and external feeds and shared files from social media and other collaboration tools to deliver accurate and complete archiving, proactive analysis, real-time review auditing and remediation.
SafeGuard™ collects activity feeds, posts and documents from social platforms, and other enterprise interactions, to proactively identify and classify business and compliance risk. An intuitive interface enables the efficient management of compliance cases with classification of risk level according to industry driven and company-defined priorities.
“Social platforms are revolutionizing business by improving a company’s ability to collaborate internally and with customers, reduce costs and improve a product’s competitive advantage,” said Jim Zuffoletti, President, OpenQ. “However, many companies are fearful of leaking trade secrets, incurring liabilities, or committing compliance violations and have been slow to go ‘Social’. With SafeGuard companies that are concerned with regulatory compliance, privacy, internal communication firewalls and brand consistency can embrace Social business and be confident that they are getting proactive, real-time risk analysis, classification and archiving.”
Added Otavio Freire, Chief Technology Officer, OpenQ. “SafeGuard enables faster enterprise adoption of social collaboration and allows companies to benefit from the value created by new, social technologies for today and tomorrow. SafeGuard can work as a stand-alone system or be integrated into current social media search and archiving tools. Most importantly, SafeGuard allows you to create social policies for specific channels and enforce the policies guaranteeing that they stand-up to internal audit processes.”
The product was discussed during a complimentary webinar "Leveraging Social Media Communities for Compliant Collaboration with Specialty Key Opinion Leaders" with Pharmaceutical Executive magazine, yesterday and can be viewed on-demand for free at www.pharmexec.com/socialmedia.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
2 Commerce Drive
Cranbury, NJ 08512